Connect with us

Technology

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production

Published

3 months ago

on

Advancing CEPI’s 100 Days Mission to Accelerate Vaccine Development

DUSSELDORF, Germany, Oct. 2, 2024 /PRNewswire/ — LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities and expedite vaccine production.

This collaboration is part of the expansion in scope of LenioBio’s CEPI-funded project, which aims to showcase the capacity and speed of LenioBio’s proprietary ALiCE® protein expression technology to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI.

The project extension follows a successful first six months during which LenioBio achieved all key milestones. They successfully demonstrated  ALiCE®’s ability to reliably produce vaccine-relevant proteins at small scales from cell-free DNA formats, and developed a suite of novel quality control assays to ensure the highest standards of product integrity and safety throughout the protein production process.

Building on this success, LenioBio will be collaborating with ReciBioPharm to achieve scaled production of vaccine proteins using ALiCE®. ReciBioPharm’s expertise in process development and manufacturing of complex biologics, along with its global footprint, will be instrumental in unlocking the full potential of ALiCE® for vaccine manufacturing and pave the path towards future GMP applications.

“Being involved in the 100 Days Mission is both an honor and a significant responsibility,” said André Goerke, CEO of LenioBio. “Our collaboration with ReciBioPharm brings us one step closer to making the vision of rapid vaccine development a reality. By transferring protein production with ALiCE® to a leading CDMO, we aim to meet the urgent need for swift vaccine production, crucial for containing emerging health threats.”

The newly announced collaboration will include technology transfer for 10-liter scale protein production of a vaccine candidate, using ALiCE®- including both upstream and downstream unit operations – to ReciBiopharm’ site in Oeiras, Portugal. This process will involve initial process and analytical method transfer and will deliver material to be used in pre-clinical studies. Establishing the ALiCE® technology in a scaled manufacturing environment is a critical first step in a roadmap toward GMP and the production of material for clinical trials and vaccine manufacture.

Vikas Gupta, president, ReciBioPharm, said: “Our collaboration with LenioBio represents a significant step forward in recombinant protein manufacturing. LenioBio’s ALiCE® technology is well-positioned to make a meaningful impact on global health, and accelerate the development of vaccines and other critical biologics. ReciBioPharm is glad to play a crucial role in proving LenioBio’s innovative platform at-scale and look forward a future where such technology will be used in clinical trials. This partnership perfectly aligns with our commitment to innovation. We are making the vision of a future where vaccines can be developed and deployed more rapidly in response to emerging threats, a reality.”

Looking ahead, LenioBio plans to conduct in-depth evaluations of ALiCE®-produced protein quality through in vivo studies focusing on dosage and efficacy. The company also intends to engage in further regulatory discussions to position ALiCE® as a platform technology for expedited development of protein medicines, aiming to reduce the time it takes for vaccines and therapeutics to reach clinical trials.

The 100 Days Mission:

The 100 Days Mission, spearheaded by CEPI and embraced by global leaders in the G7 and G20, seeks to dramatically shorten the vaccine development timeline. By reducing the time it took to develop the first licensed COVID-19 vaccines by two-thirds, this initiative has the potential to prevent future epidemics from escalating into pandemics.

About LenioBio

LenioBio is a life sciences biotech company, pioneering a disruptive protein expression platform. Using ALiCE® technology, enabling customers – researchers and biopharma manufacturers to streamline and accelerate their protein discovery, development, and production processes. LenioBio simplifies manufacturing and speeds up the delivery of drugs to the patients.

About ReciBioPharm

ReciBioPharm, a division of Recipharm, is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Led by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.

Logo – https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/leniobio-collaborates-with-recibiopharm-to-scale-up-alice-technology-and-expedite-vaccine-production-302264458.html

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MagFone Christmas & New Year Sale: Unbeatable Discounts for the Holiday Season

Published

4 hours ago

on

December 22, 2024

By

The festive season is upon us, and MagFone is here to make your holidays even brighter with an exclusive Christmas & New Year sale! From incredible discounts on best-selling products to special deals on new products, MagFone is the ultimate destination for holiday shopping. From December 18, 2024 to January 6, 2025, this sale offers up to 80% off discount for everyone. Let’s dive into the details of the most awaited sale of the year.

HONGKONG, Dec. 21, 2024 /PRNewswire-PRWeb/ — What Can You Get from MagFone Christmas & New Year Sale?

New arrival – Location Changer is only $1.99 to everyone in this MagFone Christmas & New Year Grand sales. Moreover, everyone can enjoy up to 80% OFF.

1. Best-Selling Products at Up to 70% OFF

Resolving various iOS system issues or unlocking locked Apple devices like iPhone and iPad by yourself at home with MagFone’s flagship products, now available at unbeatable prices. Best-selling products such as iPhone Unlocker, Activation Unlocker, and iOS System Recovery are up for grabs with discounts of up to 70% off. Don’t miss out on this chance to get MagFone’s best-selling products at jaw-dropping prices.

MagFone iPhone Unlocker at $20.95/month and $41.95/lifetime.MagFone Activation Unlocker at $20.95/month and $41.95/lifetime.MagFone iOS System Recovery at $17.95/month and $48.95/lifetime.

2. New Arrival to Get with Only $1.99

Whether you want to change your location on your mobile device or simulate GPS movement in various games, MagFone’s new product – Location Changer – is perfect for you. Designed for both iOS and Android users, this tool comes equipped with advanced location changing features, flexible movement speed, and customizable route. With only $1.99, it is a must-have for this Christmas sale if you have the demand to change your device location.

3. 4-in-1 Bundle to Maximize Your Savings

MagFone values all loyal customers and offers exclusive pers during the Christmas & New Year sale. A super 4-in-in bundle is at reduced prices, which enables you to get all products from MagFone with an 80% off discount. This bundle includes all the tools you need, whether you’re looking to resolve various system problems and unlocking issues or change iPhone and Android device’s location. Don’t miss this chance to get all MagFone products at unbeatable prices.

MagFone Christmas & New Year Sale is a limited-time event, running from December 18, 2024 to January 6, 2025. With discount this good, products are expected to get at the lowest price this year. Don’t wait until the last minute—start shopping now to get MagFone products at the best deals.

About MagFone:

MagFone is redefining tech innovation with state-of-the-art technology and intuitive design. Whether their flagship products like iPhone Unlocker or newly-released tools like Location Changer, MagFone products are built for performance and flexibility.

YouTube: https://www.youtube.com/@magfone

Facebook: https://www.facebook.com/magfone/

X: https://x.com/magfone

Media Contact

Olivia Wood, MagFone, 86 19186985874, support@magfone.com, https://www.magfone.com/

View original content to download multimedia:https://www.prweb.com/releases/magfone-christmas–new-year-sale-unbeatable-discounts-for-the-holiday-season-302337015.html

SOURCE MagFone

Continue Reading

Technology

Dr. Ashley Milhizer Sees 300% Growth in 2024 at Real Results Medical & Aesthetics

Published

9 hours ago

on

December 21, 2024

By

After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

TEMPE, Ariz., Dec. 21, 2024 /PRNewswire-PRWeb/ — After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business.”

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business,” said Dr. Ashley Milhizer, Founder of Real Results Medical & Aesthetics.

On both platforms, Dr. Milhizer shares educational videos and insights into various medical & aesthetic procedures. Her engaging content not only highlights the quality of care she provides but also educates her audience on the latest trends and treatments in the field.

Originally from Michigan, and a graduate of UC Davis and the Southwest College of Naturopathic Medicine & Health Sciences, it was Dr. Milhizer’s personal experience in seeing how natural remedies can significantly impact the body that inspired her to get into the field.

“While I was in school, a friend of mine was diagnosed with stage 3 cancer and was given up to 18 months to live and I became determined to research every kind of remedy that could potentially help,” said Dr. Milhizer. “From a healthy diet, supplements and a host of other naturopathic strategies, we tried everything we could find and two months later he was in remission, and he’s still alive today.”

The power of naturopathic remedies, following an early career path in sports medicine – which enabled her to work with some of the state’s top professional athletes – is what led her to forming Real Results Medical & Aesthetics. The company’s broad depth of services is also what allowed her to expand her reach of clientele beyond athletes to everyone from the Valley’s elite CEOs and stay at home Moms to patients ranging from their early 20s to upper 80s.

The naturopathic services offered at Real Results Medical & Aesthetics include hormone optimization, peptide therapy, IV therapy, natural pain relief, weight loss, food allergy testing and overall diagnostic testing. While the aesthetics side of the business offers services such as hair restoration, skin resurfacing, botox, fillers, microneedling, RF Plasma skin resurfacing, laser treatments, vein removal and body contouring.

For more information on Real Results Medical & Aesthetics, visit www.realresultsmedical.com or call/text 480.245.5636. For ongoing news, updates and service offerings, follow Dr. Milhizer on Facebook, Instagram and LinkedIn.

Media Contact

Kendra Riley, Real Results Medical & Aesthetics, 1 4802206051, kendra@dawningpr.com 

View original content to download multimedia:https://www.prweb.com/releases/dr-ashley-milhizer-sees-300-growth-in-2024-at-real-results-medical–aesthetics-302337009.html

SOURCE Real Results Medical & Aesthetics

Continue Reading

Technology

ICEYE expands its Earth Observation capabilities with launch of two SAR satellites for mid-inclination orbit on the Bandwagon-2 mission with SpaceX

Published

14 hours ago

on

December 21, 2024

By

Mid-inclination orbit provides more SAR-imaging opportunities at middle latitudes of the globe for ICEYE customers.

HELSINKI, Finland, Dec. 21, 2024 /PRNewswire/ — ICEYE, the global leader in SAR satellite operations for Earth Observation and persistent monitoring, announced today that it has launched two new satellites to its constellation of SAR satellites. Both satellites expand the availability of ICEYE’s latest imaging technology to deliver additional 25 cm imaging capacity. The satellites were integrated via Exolaunch and launched as part of the Bandwagon-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California, USA. Both satellites have established communication, and early routine operations are underway. With today’s launch, ICEYE has successfully launched 40 satellites into orbit since 2018, with nine satellites launched in 2024 alone.

The new SAR satellites were launched into mid-inclination orbits; compared to a polar orbit, these mid-inclination orbits provide more than twice the collection opportunities at middle latitudes of the globe. ICEYE customers have many areas of interest in these middle latitudes (+/- 45 degrees), and these customers will benefit from increased persistence over these regions. Customers with imaging interests outside these middle latitudes will continue to benefit from the frequent revisit enabled by ICEYE’s dozens of satellites in polar orbits. ICEYE’s unique mix of mid-inclination and polar orbits provides its customers with deep revisit capabilities for targets all around the globe. The new satellites will serve ICEYE’s commercial missions as part of the world’s largest SAR satellite constellation owned and operated by ICEYE.

Rafal Modrzewski, CEO and Co-founder of ICEYE said: “This launch marks another significant milestone in ICEYE’s ability to provide our customers with a rich diversity of collection opportunities. We bolster our industry-leading SAR constellation and expand our customers’ collection opportunities in the areas most important to them.”

Today’s launch is another step forward in ICEYE’s steady drumbeat of innovative breakthroughs in Earth Observation. This year alone, ICEYE has, for example, introduced Dwell Precise, a new 25 cm imaging mode that offers its customers the highest-fidelity 25cm imaging capability, and adds advanced capability to ICEYE’s line of Dwell products; launched an API that allows customers to directly task its SAR satellite constellation; and launched ICEYE Ocean Vision to provide actionable intelligence for maritime domain awareness.

About ICEYE

ICEYE delivers unparalleled persistent monitoring capabilities to detect and respond to changes in any location on Earth, faster and more accurately than ever before.

Owning the world’s largest synthetic aperture radar (SAR) satellite constellation, ICEYE provides objective, near real-time insights, ensuring that customers have unmatched access to actionable high-quality data, day or night, even in challenging environmental conditions. As a trusted partner to governments and commercial industries, ICEYE delivers intelligence in sectors such as insurance, natural catastrophe response and recovery, security, maritime monitoring, and finance, enabling decision-making that contributes to community resilience and sustainable development.

ICEYE operates internationally with offices in Finland, Poland, Spain, the UK, Australia, Japan, UAE, Greece, and the US.  We have more than 700 employees, inspired by the shared vision of improving life on Earth by becoming the global source of truth in Earth Observation.

Media contact: press@iceye.com

Visit www.iceye.com and follow ICEYE on LinkedIn and X for the latest updates and insights.

View original content to download multimedia:https://www.prnewswire.com/news-releases/iceye-expands-its-earth-observation-capabilities-with-launch-of-two-sar-satellites-for-mid-inclination-orbit-on-the-bandwagon-2-mission-with-spacex-302337876.html

SOURCE ICEYE

Continue Reading

Trending